Description
KST-6051 is a novel therapeutic compound designed to target KRAS-mutated solid tumors, including colorectal cancer. This agent represents a new approach to treating CRC patients whose tumors harbor KRAS mutations, which historically have been considered "undruggable" targets. The compound is currently in early-phase clinical development specifically for advanced solid tumors with confirmed KRAS mutations. KRAS mutations are present in approximately 40-50% of colorectal cancers and are associated with resistance to certain targeted therapies.
Mechanism of Action
KST-6051 appears to target the KRAS signaling pathway, though the specific molecular mechanism has not been fully disclosed in available clinical data. The compound likely works by interfering with KRAS protein function or downstream signaling cascades that drive tumor cell proliferation and survival in KRAS-mutated cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.